Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Co.'s primary product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has shown effects and has demonstrated clinical results as an agent in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of H. pylori infection. The PHAT stock yearly return is shown above.
The yearly return on the PHAT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PHAT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|